000147664 001__ 147664
000147664 005__ 20240229123026.0
000147664 0247_ $$2doi$$a10.1007/s00520-019-05120-5
000147664 0247_ $$2pmid$$apmid:31736000
000147664 0247_ $$2ISSN$$a0941-4355
000147664 0247_ $$2ISSN$$a1433-7339
000147664 0247_ $$2altmetric$$aaltmetric:71457494
000147664 037__ $$aDKFZ-2019-02653
000147664 041__ $$aeng
000147664 082__ $$a610
000147664 1001_ $$0P:(DE-He78)328b8f61d3a303a206d0813eb0387848$$aAdam, Salome$$b0$$eFirst author
000147664 245__ $$aAge-specific health-related quality of life in disease-free long-term prostate cancer survivors versus male population controls-results from a population-based study.
000147664 260__ $$aNew York,NY$$bSpringer$$c2020
000147664 3367_ $$2DRIVER$$aarticle
000147664 3367_ $$2DataCite$$aOutput Types/Journal article
000147664 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1601370614_10578
000147664 3367_ $$2BibTeX$$aARTICLE
000147664 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000147664 3367_ $$00$$2EndNote$$aJournal Article
000147664 500__ $$a2020 Jun;28(6):2875-2885.#EA:C071#LA:C071#
000147664 520__ $$aProstate cancer (PC) and its treatment may affect PC survivors differently with respect to age. However, little is known regarding age-specific health-related quality of life (HRQoL) in PC survivors 5 years or even ≥ 10 years post-diagnosis.The sample included 1975 disease-free PC survivors (5-16 years post-diagnosis) and 661 cancer-free population controls, recruited from two German population-based studies (CAESAR+, LinDe). HRQoL in both populations was assessed using the EORTC QLQ-C30 questionnaire. Additionally, PC survivors completed the PC-specific EORTC QLQ-PR25 questionnaire. Differences in HRQoL between survivors and controls, as well as differences according to age and time since diagnosis were analyzed with multiple regression after adjustment for age, education, stage, and time since diagnosis, where appropriate.In general, PC survivors reported HRQoL and symptom-burden levels comparable to the general population, except for significantly poorer social functioning and higher burden for diarrhea and constipation. In age-specific analyses, PC survivors up to 69 years indicated poorer global health and social functioning than population controls. Stratification by time since diagnosis revealed little difference between the subgroups. On PC-specific symptoms, burden was highest for urinary bother and symptoms, and lowest for bowel symptoms. Younger age was associated with less urinary symptoms but higher urinary bother.Long-term disease-free PC survivors reported overall good HRQoL, but experienced persistent specific detriments. Our data suggest that these detriments do not improve substantially with increasing time since diagnosis. Targeted interventions are recommended to prevent PC-related and treatment-related symptoms becoming chronic and to enhance social functioning.
000147664 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000147664 588__ $$aDataset connected to CrossRef, PubMed,
000147664 7001_ $$aDoege, Daniela$$b1
000147664 7001_ $$0P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aKoch-Gallenkamp, Lena$$b2$$udkfz
000147664 7001_ $$aThong, Melissa S Y$$b3
000147664 7001_ $$aBertram, Heike$$b4
000147664 7001_ $$aEberle, Andrea$$b5
000147664 7001_ $$aHolleczek, Bernd$$b6
000147664 7001_ $$aPritzkuleit, Ron$$b7
000147664 7001_ $$aWaldeyer-Sauerland, Mechthild$$b8
000147664 7001_ $$aWaldmann, Annika$$b9
000147664 7001_ $$aZeissig, Sylke Ruth$$b10
000147664 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b11$$udkfz
000147664 7001_ $$aRohrmann, Sabine$$b12
000147664 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b13$$udkfz
000147664 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b14$$eLast author$$udkfz
000147664 773__ $$0PERI:(DE-600)1463166-0$$a10.1007/s00520-019-05120-5$$n6$$p2875-2885$$tSupportive care in cancer$$v28$$x1433-7339$$y2020
000147664 909CO $$ooai:inrepo02.dkfz.de:147664$$pVDB
000147664 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)328b8f61d3a303a206d0813eb0387848$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000147664 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000147664 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000147664 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000147664 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000147664 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000147664 9141_ $$y2020
000147664 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000147664 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000147664 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000147664 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000147664 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSUPPORT CARE CANCER : 2017
000147664 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000147664 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000147664 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000147664 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000147664 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000147664 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000147664 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000147664 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000147664 9202_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000147664 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000147664 9200_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000147664 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000147664 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000147664 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000147664 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000147664 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x3
000147664 980__ $$ajournal
000147664 980__ $$aVDB
000147664 980__ $$aI:(DE-He78)C071-20160331
000147664 980__ $$aI:(DE-He78)C070-20160331
000147664 980__ $$aI:(DE-He78)HD01-20160331
000147664 980__ $$aI:(DE-He78)C120-20160331
000147664 980__ $$aUNRESTRICTED